Evidence-based initiation of dopaminergic therapy in Parkinson's disease
Identifieur interne : 001D15 ( Main/Exploration ); précédent : 001D14; suivant : 001D16Evidence-based initiation of dopaminergic therapy in Parkinson's disease
Auteurs : Janis M. Miyasaki [Canada]Source :
- Journal of neurology. Supplement [ 0939-1517 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and involuntary motor movements. Dopamine agonists reduce the risk of development of motor complications in the 5-year term. However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000357
- to stream PascalFrancis, to step Curation: 000906
- to stream PascalFrancis, to step Checkpoint: 000356
- to stream Main, to step Merge: 001E46
- to stream Main, to step Curation: 001D15
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evidence-based initiation of dopaminergic therapy in Parkinson's disease</title><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M." last="Miyasaki">Janis M. Miyasaki</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Movement Disorders Centre, Toronto Western Hospital, University Health Network, 399 Bathurst Street, 7 McLaughlin</s1><s2>Toronto, ON M5T 2S8</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, ON M5T 2S8</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0034036</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 11-0034036 INIST</idno><idno type="RBID">Pascal:11-0034036</idno><idno type="wicri:Area/PascalFrancis/Corpus">000357</idno><idno type="wicri:Area/PascalFrancis/Curation">000906</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000356</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000356</idno><idno type="wicri:doubleKey">0939-1517:2010:Miyasaki J:evidence:based:initiation</idno><idno type="wicri:Area/Main/Merge">001E46</idno><idno type="wicri:Area/Main/Curation">001D15</idno><idno type="wicri:Area/Main/Exploration">001D15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evidence-based initiation of dopaminergic therapy in Parkinson's disease</title><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M." last="Miyasaki">Janis M. Miyasaki</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Movement Disorders Centre, Toronto Western Hospital, University Health Network, 399 Bathurst Street, 7 McLaughlin</s1><s2>Toronto, ON M5T 2S8</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, ON M5T 2S8</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of neurology. Supplement</title><title level="j" type="abbreviated">J. neurol., Suppl.</title><idno type="ISSN">0939-1517</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of neurology. Supplement</title><title level="j" type="abbreviated">J. neurol., Suppl.</title><idno type="ISSN">0939-1517</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term><term>Levodopa</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Traitement</term><term>Stimulant dopaminergique</term><term>Lévodopa</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and involuntary motor movements. Dopamine agonists reduce the risk of development of motor complications in the 5-year term. However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M." last="Miyasaki">Janis M. Miyasaki</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0034036
|texte= Evidence-based initiation of dopaminergic therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |